HRP20230998T1 - Novi derivati ftalazinona i postupak njihove proizvodnje - Google Patents
Novi derivati ftalazinona i postupak njihove proizvodnje Download PDFInfo
- Publication number
- HRP20230998T1 HRP20230998T1 HRP20230998TT HRP20230998T HRP20230998T1 HR P20230998 T1 HRP20230998 T1 HR P20230998T1 HR P20230998T T HRP20230998T T HR P20230998TT HR P20230998 T HRP20230998 T HR P20230998T HR P20230998 T1 HRP20230998 T1 HR P20230998T1
- Authority
- HR
- Croatia
- Prior art keywords
- carbonyl
- phthalazin
- compound
- azetidin
- fluorobenzyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- -1 methylene, carbonyl Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- KKSZOZGTFLMQIZ-UHFFFAOYSA-N C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F KKSZOZGTFLMQIZ-UHFFFAOYSA-N 0.000 claims 2
- DKJMZXNQISEHFU-UHFFFAOYSA-N C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F DKJMZXNQISEHFU-UHFFFAOYSA-N 0.000 claims 2
- GKUXCCVQBLJTMD-MRXNPFEDSA-N C1(CC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F GKUXCCVQBLJTMD-MRXNPFEDSA-N 0.000 claims 2
- XESQDDBWEOEUDO-UHFFFAOYSA-N C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F XESQDDBWEOEUDO-UHFFFAOYSA-N 0.000 claims 2
- YCAPBAODPGKNAI-UHFFFAOYSA-N C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F YCAPBAODPGKNAI-UHFFFAOYSA-N 0.000 claims 2
- XZUMNWIZCNUMAS-GOSISDBHSA-N C1(CCCC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CCCC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F XZUMNWIZCNUMAS-GOSISDBHSA-N 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- IGINPWSVDNTKOK-UHFFFAOYSA-N Cl.C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F IGINPWSVDNTKOK-UHFFFAOYSA-N 0.000 claims 2
- PNQARVCRZIKCHP-UHFFFAOYSA-N Cl.C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F PNQARVCRZIKCHP-UHFFFAOYSA-N 0.000 claims 2
- FSVSACOGQQIXAF-UHFFFAOYSA-N Cl.C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F FSVSACOGQQIXAF-UHFFFAOYSA-N 0.000 claims 2
- UBSLSGKRSOQQKE-UHFFFAOYSA-N Cl.C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F UBSLSGKRSOQQKE-UHFFFAOYSA-N 0.000 claims 2
- OSXBCQJXDXZASP-UHFFFAOYSA-N Cl.C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F OSXBCQJXDXZASP-UHFFFAOYSA-N 0.000 claims 2
- HPHLEONXLLWYKF-UHFFFAOYSA-N Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C Chemical compound Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C HPHLEONXLLWYKF-UHFFFAOYSA-N 0.000 claims 2
- KTJXLDNKRDIIKT-UHFFFAOYSA-N Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C Chemical compound Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C KTJXLDNKRDIIKT-UHFFFAOYSA-N 0.000 claims 2
- HQGFJTPHAXRFJN-UHFFFAOYSA-N Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C Chemical compound Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C HQGFJTPHAXRFJN-UHFFFAOYSA-N 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- LWCQZYNHAVNPAH-UHFFFAOYSA-N FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C LWCQZYNHAVNPAH-UHFFFAOYSA-N 0.000 claims 2
- JFCUZMQKURGQOK-UHFFFAOYSA-N FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C JFCUZMQKURGQOK-UHFFFAOYSA-N 0.000 claims 2
- DSBIAGOLCXYHPB-UHFFFAOYSA-N FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C DSBIAGOLCXYHPB-UHFFFAOYSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- YNBQAYKYNYRCCA-UHFFFAOYSA-N venadaparib Chemical compound C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F YNBQAYKYNYRCCA-UHFFFAOYSA-N 0.000 claims 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- OOGCIODHIGNQIQ-UHFFFAOYSA-N 4-[[4-fluoro-3-[3-[[1-(trifluoromethyl)cyclopropyl]amino]azetidine-1-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(C1)CC1NC1(C(F)(F)F)CC1 OOGCIODHIGNQIQ-UHFFFAOYSA-N 0.000 claims 1
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical group C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130110170 | 2013-09-13 | ||
| KR1020140120152A KR101670126B1 (ko) | 2013-09-13 | 2014-09-11 | 신규 프탈라지논 유도체 및 그 제조방법 |
| EP14843941.7A EP3030557B1 (en) | 2013-09-13 | 2014-09-12 | A novel phtalazinone derivatives and manufacturing process thereof |
| PCT/KR2014/008523 WO2015037939A1 (en) | 2013-09-13 | 2014-09-12 | A novel phtalazinone derivatives and manufacturing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230998T1 true HRP20230998T1 (hr) | 2023-12-08 |
Family
ID=53024930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230998TT HRP20230998T1 (hr) | 2013-09-13 | 2014-09-12 | Novi derivati ftalazinona i postupak njihove proizvodnje |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | USRE49338E1 (enExample) |
| EP (1) | EP3030557B1 (enExample) |
| JP (1) | JP6180643B2 (enExample) |
| KR (1) | KR101670126B1 (enExample) |
| CN (1) | CN105793248B (enExample) |
| AU (1) | AU2014319132C1 (enExample) |
| BR (1) | BR112016004979B1 (enExample) |
| CA (1) | CA2923614C (enExample) |
| DK (1) | DK3030557T3 (enExample) |
| ES (1) | ES2953834T3 (enExample) |
| FI (1) | FI3030557T3 (enExample) |
| HR (1) | HRP20230998T1 (enExample) |
| HU (1) | HUE062770T2 (enExample) |
| IL (1) | IL244548B (enExample) |
| LT (1) | LT3030557T (enExample) |
| MX (1) | MX379467B (enExample) |
| MY (1) | MY195343A (enExample) |
| PL (1) | PL3030557T3 (enExample) |
| PT (1) | PT3030557T (enExample) |
| RS (1) | RS64477B1 (enExample) |
| RU (1) | RU2636585C2 (enExample) |
| SG (1) | SG11201600549TA (enExample) |
| SI (1) | SI3030557T1 (enExample) |
| SM (1) | SMT202300268T1 (enExample) |
| WO (1) | WO2015037939A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| JP2021516229A (ja) | 2018-02-28 | 2021-07-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤 |
| CN115702151B (zh) * | 2020-04-21 | 2025-03-11 | 伊迪恩斯股份有限公司 | 酞嗪酮化合物的结晶形式 |
| EP4139298A4 (en) * | 2020-04-21 | 2024-05-22 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| WO2021225407A1 (ko) * | 2020-05-08 | 2021-11-11 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| US12059419B2 (en) * | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US20230391752A1 (en) * | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| KR20220125183A (ko) | 2021-03-04 | 2022-09-14 | 아이디언스 주식회사 | Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도 |
| TWI883310B (zh) * | 2021-03-04 | 2025-05-11 | 南韓商愛迪恩斯股份有限公司 | 酞嗪酮化合物在製備用於治療人類奧拉帕尼抗藥性癌症之藥物的用途 |
| US20250312342A1 (en) * | 2021-06-02 | 2025-10-09 | Idience Co., Ltd. | Methods of treating disorders with phthalazinone derivatives |
| US20250120970A1 (en) * | 2022-01-25 | 2025-04-17 | Idience Co., Ltd. | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |
| WO2024025389A1 (ko) * | 2022-07-29 | 2024-02-01 | 아이디언스 주식회사 | 프탈라지논 유도체의 중간체의 제조방법 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155645A0 (en) | 2000-10-30 | 2003-11-23 | Kudos Pharm Ltd | Phthalazinone derivatives |
| JP4500161B2 (ja) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| EP1633724B1 (en) * | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| AU2007266840B2 (en) | 2006-05-31 | 2012-09-20 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP) |
| DK2698062T3 (en) | 2006-12-28 | 2015-09-14 | Abbvie Inc | Poly (ADP-ribose) polymerase inhibitors |
| CN101030723A (zh) | 2007-04-04 | 2007-09-05 | 钟志华 | 电磁变相发动机 |
| ES2524787T3 (es) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2012014221A1 (en) | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US8999985B2 (en) * | 2010-12-02 | 2015-04-07 | Shanghai De Novo Pharmatech Co Ltd. | Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
-
2014
- 2014-09-11 KR KR1020140120152A patent/KR101670126B1/ko active Active
- 2014-09-12 HU HUE14843941A patent/HUE062770T2/hu unknown
- 2014-09-12 CN CN201480049174.5A patent/CN105793248B/zh active Active
- 2014-09-12 MY MYPI2016700730A patent/MY195343A/en unknown
- 2014-09-12 FI FIEP14843941.7T patent/FI3030557T3/fi active
- 2014-09-12 SM SM20230268T patent/SMT202300268T1/it unknown
- 2014-09-12 ES ES14843941T patent/ES2953834T3/es active Active
- 2014-09-12 EP EP14843941.7A patent/EP3030557B1/en active Active
- 2014-09-12 MX MX2016002998A patent/MX379467B/es unknown
- 2014-09-12 RU RU2016108038A patent/RU2636585C2/ru active
- 2014-09-12 JP JP2016542643A patent/JP6180643B2/ja active Active
- 2014-09-12 US US16/447,174 patent/USRE49338E1/en active Active
- 2014-09-12 LT LTEPPCT/KR2014/008523T patent/LT3030557T/lt unknown
- 2014-09-12 DK DK14843941.7T patent/DK3030557T3/da active
- 2014-09-12 AU AU2014319132A patent/AU2014319132C1/en active Active
- 2014-09-12 CA CA2923614A patent/CA2923614C/en active Active
- 2014-09-12 HR HRP20230998TT patent/HRP20230998T1/hr unknown
- 2014-09-12 BR BR112016004979-9A patent/BR112016004979B1/pt active IP Right Grant
- 2014-09-12 SG SG11201600549TA patent/SG11201600549TA/en unknown
- 2014-09-12 RS RS20230721A patent/RS64477B1/sr unknown
- 2014-09-12 US US15/021,336 patent/US9682973B2/en active Active
- 2014-09-12 PT PT148439417T patent/PT3030557T/pt unknown
- 2014-09-12 WO PCT/KR2014/008523 patent/WO2015037939A1/en not_active Ceased
- 2014-09-12 SI SI201432038T patent/SI3030557T1/sl unknown
- 2014-09-12 PL PL14843941.7T patent/PL3030557T3/pl unknown
-
2016
- 2016-03-11 IL IL244548A patent/IL244548B/en active IP Right Grant
-
2017
- 2017-03-10 US US15/455,631 patent/US9844550B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230998T1 (hr) | Novi derivati ftalazinona i postupak njihove proizvodnje | |
| JP2012097115A5 (enExample) | ||
| JP2016516699A5 (enExample) | ||
| MX2012002875A (es) | Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos. | |
| PH12014502420A1 (en) | Iap bir domain binding compound | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| NZ630875A (en) | Heterocyclic compounds and uses thereof | |
| EA201591239A1 (ru) | Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1 | |
| JP2011525192A5 (enExample) | ||
| HRP20140814T1 (hr) | Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma | |
| FI2501384T4 (fi) | Menetelmä bcr-abl-, c-kit-, ddr1-, ddr2- tai pdgf-r-kinaasiaktiivisuuden välittämien proliferatiivisten häiriöiden ja muiden patologisten tilojen hoitamiseksi | |
| HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2015504091A5 (enExample) | ||
| UA115881C2 (uk) | Алкоксипіразоли як активатори розчинної гуанілатциклази | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| UA122552C2 (uk) | Композиція та спосіб для боротьби з захворюваннями, спричиненими фітопатогенами | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| HRP20201985T1 (hr) | Piridonski spoj kao c-met inhibitor | |
| JP2016534143A5 (enExample) | ||
| JP2019530708A5 (enExample) | ||
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| ATE535241T1 (de) | Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie |